Packe G E, Douglas J G, McDonald A F, Robins S P, Reid D M
Department of Thoracic Medicine, Aberdeen Royal Infirmary.
Thorax. 1992 Jun;47(6):414-7. doi: 10.1136/thx.47.6.414.
Asthmatic patients taking low to moderate doses of inhaled topical corticosteroids have been shown to have lower bone density than those taking bronchodilators only. There is little information on bone density in asthmatic patients taking high dose inhaled corticosteroids.
Bone mass was studied in three age matched groups of asthmatic patients. These comprised: 17 asthmatic patients who had never taken inhaled or systemic corticosteroids (group 1); 20 patients who had taken beclomethasone diproprionate in a dosage of 1000-2000 micrograms daily for at least a year, who had also received courses of systemic corticosteroids in the past (group 2); and 20 patients who were taking both high dose inhaled corticosteroids and regular low dose prednisolone, at a median dose of 7 mg daily (group 3). Vertebral bone density was measured by quantitative computed tomography. Biochemical indices of bone formation and resorption were also measured.
Mean bone density in group 2 (127.5(22.6) mg/ml) was similar to that in group 3 (114.5 (36.0) mg/ml). Bone density was significantly lower in both of these groups than in group 1 (160.4 (27.4) mg/ml). There were no significant differences between groups for any of the markers of bone formation and resorption.
Asthmatic patients receiving high dose inhaled beclomethasone and intermittent courses of systemic corticosteroids have reduced vertebral bone density. The bone loss is similar in degree to that seen in patients taking high dose inhaled topical corticosteroids and continuous low dose systemic corticosteroids.
研究表明,服用低至中等剂量吸入性局部糖皮质激素的哮喘患者的骨密度低于仅服用支气管扩张剂的患者。关于服用高剂量吸入性糖皮质激素的哮喘患者的骨密度信息很少。
对三组年龄匹配的哮喘患者进行骨量研究。这些组包括:17名从未服用过吸入性或全身性糖皮质激素的哮喘患者(第1组);20名每天服用1000 - 2000微克丙酸倍氯米松至少一年且过去也接受过全身性糖皮质激素疗程治疗的患者(第2组);以及20名同时服用高剂量吸入性糖皮质激素和常规低剂量泼尼松龙(中位剂量为每日7毫克)的患者(第3组)。通过定量计算机断层扫描测量椎体骨密度。还测量了骨形成和骨吸收的生化指标。
第2组的平均骨密度(127.5(22.6)毫克/毫升)与第3组(114.5(36.0)毫克/毫升)相似。这两组的骨密度均显著低于第1组(160.4(27.4)毫克/毫升)。骨形成和骨吸收的任何标志物在各组之间均无显著差异。
接受高剂量吸入性倍氯米松和间歇性全身性糖皮质激素疗程治疗的哮喘患者椎体骨密度降低。骨质流失的程度与服用高剂量吸入性局部糖皮质激素和持续低剂量全身性糖皮质激素的患者相似。